Daglutril

Drug Profile

Daglutril

Alternative Names: KC 12615; SLV-306

Latest Information Update: 29 Apr 2015

Price : $50

At a glance

  • Originator Solvay Pharmaceuticals
  • Developer AbbVie
  • Class Antihypertensives; Heart failure therapies; Sulfhydryl compounds
  • Mechanism of Action Endothelin-converting enzyme 1 inhibitors; Neprilysin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Heart failure; Hypertension

Most Recent Events

  • 29 Apr 2015 Daglutril is available for licensing in World as of 29 Apr 2015.
  • 13 Feb 2013 No development reported - Phase-II for Heart failure in Germany (PO)
  • 13 Feb 2013 No development reported - Phase-II for Heart failure in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top